parallel randomized trial

S003034

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Other conditionsS003034

Design

Randomized: 52
Start year
Treatment: 6 weeks, follow-up 6 weeks
Countries: Denmark (2 sites)
Sponsor: (mixed)
Eligibility: SeHCAT 10 percent or less; no diabetes; bile acid diarrhea

Conduct and analysis

Blinding: double blind
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Liraglutide 1.8 mg subcutaneous once daily Liraglutide 1.8 mg daily	lifestyle: not reported	26
A2	Colesevelam Colesevelam 1875 mg twice daily	lifestyle: not reported	26

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Liraglutide 1.8 mg subcutaneous once daily A1	Colesevelam A2	Whole trial ALL
age	mean (years)	51.7	48.7
age	sd (years)	13.3	12.8
bmi	mean (kg/m2)	31.5	28.3
bmi	sd (kg/m2)	5.6	4.1
female	n			32

Results

4 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Discontinuation due to adverse events (2 lines; O26)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				1 / 26	not stated; randomized; R0018327:Results
	A2	events				1 / 26	not stated; randomized; R0018327:Results

Discontinuation due to gastrointestinal adverse events (2 lines; O27E)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				1 / 26	not stated; randomized; R0018327:Results
	A2	events				1 / 26	not stated; randomized; R0018327:Results